More Exercise, More Plaque?

The protocol is Brad Stanfield’s personal strategy to minimize plaque burden in light of the finding that even high-level athletes develop calcified and non-calcified plaque. He argues that managing traditional risk factors is not optional for exercisers. Using a personalized health calculator, he determined that his LDL of 1.9 mmol/L (73 mg/dL) warranted a statin. When pravastatin alone failed to bring LDL below 50–60 mg/dL, he added ezetimibe, a cholesterol absorption inhibitor. He emphasizes that he continues to exercise and views the combination of lifestyle and pharmacology as the optimal approach. He does not specify doses, but the narrative shows a willingness to escalate to reach an ambitious LDL target. The calculator he mentions is free and accessible to the audience; it provided the recommendation to start a statin and later to add ezetimibe. This example illustrates a proactive, personalized model of cardiovascular prevention that prioritizes hard endpoint reduction over reliance on fitness as a shield.

Stanfield unpacks the nuanced finding: high-intensity exercise alone wasn’t linked to high levels of plaque buildup. Instead, high training volume showed stronger connections with plaque only when it also included large amounts of high-intensity training. This suggests that it’s the combination—many hours of training that repeatedly spike heart rate—that seems to stress the arterial wall. This dovetails with the new study’s design, where training load (volume × intensity) was the metric that generated the 6× risk relationship. For physically active people who keep volume moderate, intermittent high-intensity sessions may not carry the same plaque-promoting risk. The takeaway is not that high intensity is benign in all contexts, but that the total load matters, and very high volumes of intense work appear to be the problematic zone.

The 2023 Masters at Heart Consortium included 191 lifelong endurance athletes, 191 late-onset athletes, and 176 active but non-athletic controls, all screened to exclude cardiovascular risk factors. As expected, lifelong endurance athletes had significantly more plaque in their arteries. The bombshell was that, unlike earlier hopes, they did not have a less risky form of plaque. There was no difference in plaque composition favoring stability; the athletes’ plaque was just as potentially dangerous as that of the non-athlete controls. This finding shapes the interpretation of the newer training-load study: even if athletes are not dropping dead at higher rates, they are accumulating plaque that is not inherently safer, making aggressive risk-factor management more pressing.

Brad Stanfield cites a study with over 21,000 participants followed for 17 years. High-volume exercisers were more likely to have elevated measures of plaque, matching the pattern seen in athlete cohorts. Crucially, they were not more likely to die from heart disease or other causes. In fact, there remained an overall survival advantage for those with very high training volumes. This data supports the view that the plaque burden seen on CT scans in extreme exercisers is not translating into increased cardiac mortality during the follow-up periods studied. Stanfield frames this as a compelling reason to focus on hard outcomes like death and heart attacks rather than surrogate markers like plaque scores, while also acknowledging that the long-term consequences beyond two decades are not yet known. It reinforces his core message: exercise remains overwhelmingly beneficial.

Stanfield explains that after reviewing the exercise-plaque literature, he concluded that being fit does not grant immunity from atherosclerosis. He started pravastatin at night, but his LDL only dropped to a level he considered insufficient; he then added ezetimibe (Zetia) to reach an LDL of 50–60 mg/dL. His decision was guided by a personalized risk calculator that incorporated his metrics: male, 183 cm, 83 kg, baseline LDL of 1.9 mmol/L (73 mg/dL). The calculator recommended a statin and later the addition of ezetimibe. He sees this not as ‘either exercise or drugs’ but ‘both.’ He emphasizes that this plan was discussed with a doctor, and he uses it as an example that anyone can generate a similar personalized plan. This is a stark departure from the idea that a young, lean, exercising individual needs no pharmacological prevention, and it underscores the message that markers like LDL should be managed aggressively if you want to minimize plaque formation over a lifetime.